- Home
- NTRA vs TPR Comparison
NTRA vs TPR Comparison
Compare NTRA & TPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- TPR
- Stock Information
- Founded
- NTRA 2003
- TPR 1941
- Country
- NTRA United States
- TPR United States
- Employees
- NTRA N/A
- TPR N/A
- Industry
- NTRA Medical Specialities
- TPR Apparel
- Sector
- NTRA Health Care
- TPR Consumer Discretionary
- Exchange
- NTRA Nasdaq
- TPR Nasdaq
- Market Cap
- NTRA 27.0B
- TPR 20.7B
- IPO Year
- NTRA 2015
- TPR 2000
- Fundamental
- Price
- NTRA $199.57
- TPR $103.69
- Analyst Decision
- NTRA Strong Buy
- TPR Buy
- Analyst Count
- NTRA 18
- TPR 18
- Target Price
- NTRA $208.94
- TPR $116.94
- AVG Volume (30 Days)
- NTRA 1.3M
- TPR 3.0M
- Earning Date
- NTRA 11-06-2025
- TPR 11-06-2025
- Dividend Yield
- NTRA N/A
- TPR 1.54%
- EPS Growth
- NTRA N/A
- TPR N/A
- EPS
- NTRA N/A
- TPR 1.25
- Revenue
- NTRA $2,116,676,000.00
- TPR $7,207,800,000.00
- Revenue This Year
- NTRA $25.70
- TPR $4.06
- Revenue Next Year
- NTRA $15.42
- TPR $4.48
- P/E Ratio
- NTRA N/A
- TPR $82.89
- Revenue Growth
- NTRA 38.17
- TPR 8.14
- 52 Week Low
- NTRA $125.38
- TPR $49.84
- 52 Week High
- NTRA $203.23
- TPR $118.56
- Technical
- Relative Strength Index (RSI)
- NTRA 69.72
- TPR 37.65
- Support Level
- NTRA $193.29
- TPR $93.00
- Resistance Level
- NTRA $203.23
- TPR $109.96
- Average True Range (ATR)
- NTRA 7.37
- TPR 3.68
- MACD
- NTRA 0.25
- TPR -1.59
- Stochastic Oscillator
- NTRA 80.29
- TPR 39.50
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About TPR Tapestry Inc.
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.